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Expression of CD90 and P75NTR stem cell 
markers in ameloblastomas: a possible 
role in their biological behavior
Abstract: Multicystic and unicystic ameloblastomas are benign 
odontogenic tumors that present distinct biological behavior. 
The investigation of stem cells has become an important branch of 
tumor biology, with several studies addressing the possible role of 
these cells in tumor growth, angiogenesis, progression, infiltration 
and invasiveness. This study evaluated the immunohistochemical 
expression of CD90(Thy-1) and P75NTR stem cell markers in 
multicystic and unicystic ameloblastomas. Seventeen (17) samples of 
ameloblastomas (multicystic, n = 10; unicystic, n = 7) were submitted 
to immunohistochemical reactions and graded semi-quantitatively. 
The Kolmogorov-Smirnov test was used to verify possible differences 
in CD90 and P75NTR expressions between multicystic and unicystic 
ameloblastomas (p < 0.05). CD90 immunostaining was observed in all 
multicystic ameloblastoma specimens (n = 10), in the cytoplasm of the 
fibroblasts and vascular endothelial cells of the tumor stroma, near the 
neoplastic odontogenic epithelia. The staining of stromal CD90 was 
significantly higher in multicystic than in unicystic ameloblastomas 
(p = 0.003). Nuclear P75NTR immunostaining was observed in all 
ameloblastoma specimens. A significant difference was seen in the 
epithelial staining of P75NTR between multicystic and unicystic types 
(p = 0.007). The increased expression of CD90 and P75NTR found in 
multicystic ameloblastomas suggests a behavioral biological difference 
between multicystic and unicystic ameloblastomas, as well as a 
difference in ameloblastoma development.
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Introduction
Ameloblastoma is a benign but locally destructive odontogenic tumor 
associated with substantial morbidities1. Clinically, the ameloblastoma can be 
classified as multicystic, unicystic, peripheral and demosplastic2. Unicystic and 
multicystic ameloblastomas are the most prevalent types of ameloblastoma 
in the jaws, whereas the multicystic type is described as the most aggressive, 
with problematic recurrences3.  In recent years, many studies have identified 
molecular alterations in the ameloblastoma4,5; however, its etiology and the 
causes of its persistent biologic behavior are still unclear.
According to the last WHO classification of odontogenic tumors, 
ameloblastomas are composed of a neoplastic odontogenic epithelium with 
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mature fibrous stroma, without neoplastic odontogenic 
ectomesenchyme2. A substantial body of studies has 
demonstrated the role of the interactions between 
stroma and neoplastic cells in tumor biology6,7,8 as 
an important event in understanding the biological 
behavior of tumors. 
There are few studies suggesting a regulatory 
role of the stromal cells in the mechanisms of local 
invasiveness of ameloblastomas9,10,11. This role is 
based on studies of epithelial mesenchymal transition 
promoters9,10 and cytokine secretion in stromal 
fibroblasts of ameloblatomas11. 
In line with the tumor and stromal cell interaction 
theory, CD90 (Thy-1), a glycosylphosphatidylinositol 
(GPI)-anchored glycoprotein emerges as an important 
mesenchymal stem cell marker that plays a major 
role in tumor-stroma interactions, influencing the 
degree of invasiveness of several types of cancers6,7,8. 
Recently, Juuri et al.12 suggested that ameloblastoma 
epithelial cells have some stem cell properties. According 
to their study, the expression of transcription factor 
SRY-related HMG-box gene 2(SOX2) in ameloblastomas 
is related to the maintenance of “stemness” in the 
tumor epithelial cells, and consequently influences 
its biological behavior. However, the authors assume 
that the analysis of a single marker is not sufficient 
to elucidate the molecular mechanism involved in 
ameloblastoma pathogenesis. 
P75 neurotrophin receptor (P75NTR) is a low-affinity 
receptor for nerve growth factors (neurotrophins and 
pro-neurotrophins), widely studied because of its 
diverse biological responses in different pathways, 
including survival, migration and differentiation of 
normal and tumor epithelial stem cells. P75NTR is 
expressed in various types of stem cells and has been 
used to isolate stem cells with different maturation 
capacity13. Moreover, P75NTR seems to be deregulated 
in mutant ameloblasts, which may participate in 
the development of an odontogenic tumor of dental 
epithelium origin14. 
Although there are some studies addressing the 
interaction between tumor-stromal cells and stem 
cell properties in ameloblastomas, there have been 
no studies that have evaluated CD90 and P75NTR 
expressions in ameloblastomas, or their biological 
behavior in relation to stem cell marker expression. 
In this context, the aim of the present study was to 
evaluate the immunohistochemical expression of 
CD90 and P75NTR stem cell markers in multicystic 
and unicystic ameloblastoma specimens.
Methodology 
Study design
Following approval of the study by the Human 
Ethics Committee of the Institutional Review Board, 
our specialized Oral Medicine and Oral Pathology 
Service searched for records of ameloblastoma cases 
between the years of 2004 and 2014. All available 
paraffin-embedded tissue samples were reviewed, and 
only the cases with satisfactory tissue and a confirmed 
diagnosis of multicystic or unicystic ameloblastomas 
were included in the sample. The clinical characteristics 
of 11 of the 17 selected cases of ameloblastoma were 
recorded, including gender, age, anatomic site, size 
(performed with radiographic exams using the 
CliniView™ software) and radiographic characteristics. 
Immunohistochemistry
Ten (10) samples of multicystic and seven (7) of 
unicystic ameloblastomas were submitted to 3 µm 
histological sections followed by dewaxing and 
rehydration in a graded ethanol series. Antigen 
retrieval was performed by immersing the sections 
in a 10 mM monohydrated citrate buffer solution 
(pH 6.0), and heating them in a water bath at 95°C 
for 30 minutes. Internal peroxidase activity was 
inhibited by 6% hydrogen peroxide and a methanol 
solution.  After washing with Tris buffer (pH 7.4), the 
slides were incubated with anti-CD90 monoclonal 
antibody (Abcam, Cambridge, MA, USA, dilution 
1:100) overnight at 4ºC, and with anti-P75NTR (Abcam, 
Cambridge, MA, US, dilution 1:100) for 30 minutes at 
room temperature. Omission of the specific primary 
antibody was used as the negative control, whereas 
breast carcinoma samples were used as the positive 
controls for both CD90 and P75NTR. The slides were 
subsequently exposed to avidin-biotin complex 
(LSAB-Kit + HRP; DakoCytomation, Carpinteria, CA, 
USA) and to 3,3′-diaminobenzidine chromogen (DAB+; 
DakoCytomation, Carpinteria, CA, USA), and were 
counterstained with Meyer’s hematoxylin, dehydrated 
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in ethanol, cleared in xylene, and mounted. Brown 
staining was considered as positive. 
The immunohistochemical expression was analyzed 
in 4 randomly selected fields at 200x magnification 
and graded semi-quantitatively, based on a modified 
score15, considering the percentage of positive cells: 
grade 0, 0–1%; grade 1, > 1–10%; grade 2, > 10–25%; 
grade 3, > 25–75%; and grade 4, > 75–100% positive cells. 
CD90 positivity was determined in the cytoplasm of 
the fibroblasts and in the vascular endothelial cells of 
the tumor stroma. P75NTR positivity was determined 
in the nucleus of the odontogenic epithelial cells. 
Here we considered only the nuclear expression 
of P75NTR, because it seems that P75NTR in the 
nucleus plays a role in ameloblast differentiation14. 
The immunohistochemical reactivity was analyzed 
by two independent, blinded and calibrated observers, 
under light microscopy at 200-fold magnification. 
Statistical analysis
The statistical analysis was performed by the 
Statistical Package for Social Sciences software (SPSS 
16, Headquarters, Chicago, IL, USA). The Kolmogorov-
Smirnov test was used to verify possible differences 
in CD90 and P75NTR expressions between multicystic 
and unicystic ameloblastomas. Spearman’s correlation 
coefficient was performed to evaluate the correlation 
between CD90 and P75NTR expressions in multicystic 
and unicystic ameloblastomas. A P-value of <0.05 
was considered statistically significant.
Results 
Clinical and pathological characteristics 
Clinical data were available for 11 of the 17 patients, 
6 being male and 5 being female, with an average 
age of 30.36 years (range of 14–47 years). Sixty-three 
percent (63.64% – n = 7) of the ameloblastomas were 
located in the posterior mandible and 36.36% (n = 4) 
in the body of the mandible, with a median size of 
78.71 mm (range of 45.3–127.4 mm).  Radiographically, 
the most common features were well-defined 
uni- or multilocular radiolucencies, mainly affecting 
the mandible (Table 1).  
CD90 expression in multicystic and 
unicystic ameloblastomas
CD90 immunostaining was observed in all the 
multicystic ameloblastoma specimens (n = 10), with 
a prominent cytoplasmic CD90 expression in the 
fibroblasts and the vascular endothelial cells of the 
tumor stroma, near the cords/nests of neoplastic 
odontogenic epithelia (Figure 1, A-B). Unicystic 
ameloblastomas showed discrete cytoplasmic 
CD90 immunostaining in the capsular connective 
tissue of the tumors, with no evident proximity 
to the neoplastic epithelium (Figure 1, C). The 
staining of stromal CD90 was signif icantly 
higher in multicystic ameloblastomas than in 
unicystic ameloblastomas (Kolmogorov-Smirnov 
test – p = 0.003) (Table 2). 
Table 1. Clinical and pathological features of the ameloblastoma sample.
Case Gender Age (years) Anatomic location Pathological type Radiographic characteristics Size (mm)
1 M 24 Body of the mandible plexiform multilocular 116,2
2 F 45 Mandibular symphisis plexiform multilocular 81,7
3 M 47 Posterior mandible follicular multilocular 49,1
4 M 35 Posterior mandible acantomathous multilocular 74,6
5 M 22 Mandibular symphisis follicular multilocular 97,4
6 M 41 Body of the mandible follicular multilocular 62,7
7 F 22 Posterior mandible luminal unilocular 45,3
8 F 20 Posterior mandible luminal unilocular 127,4
9 M 14 Posterior mandible unspecified unilocular 59,9
10 F 19 Body of the mandible unspecified unilocular 66,1
11 F 45 Posterior mandible mural unilocular 85,5
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P75NTR expression in multicystic and 
unicystic ameloblastomas
P75NTR immunostaining was observed in all 
multicystic and unicystic ameloblastoma specimens. 
In multicystic ameloblastomas, high nuclear 
P75NTR expression was detected in the central 
areas of neoplastic epithelium cords/nests, mostly 
in areas with loosely arranged cells, resembling 
the stellate reticulum (Figure 2, A), or in cells with 
squamous differentiation (Figure 2, B). P75NTR 
was also seen in the peripheral ameloblast-like 
columnar cells. 
Nuclear P75NTR expression was noted in 
the neoplastic epithelium of a few specimens of 
unicystic ameloblastomas (Figure 2, C), insofar as a 
significant difference was seen in the staining between 
multicystic and unicystic types (Kolmogorov-Smirnov 
test – P= 0.007) (Table 3). 
Discussion
Multicystic and unicystic ameloblastomas are 
benign odontogenic tumors that present distinct 
biological behavior. A comparison between the two 
histological subtypes in terms of biological behavior 
shows multicystic ameloblastoma as being more 
locally invasive, having worse prognosis and also 
having a greater tendency of recurrence1,16. On the 
other hand, unicystic lesions are the less aggressive 
type of ameloblastoma, with a better response to 
enucleation and curettage than the multicystic type17. 
The investigation of stem cells has become an 
important branch of tumor biology13, with several 
studies addressing the possible role of these cells 
Figure 1. Immunohistochemical expression of CD90 in 
multicystic and unicystic ameloblastomas. (A, B) Cytoplasmic 
CD90 expression in the fibroblasts (asterisk) and vascular 
endothelial cells of the multicystic ameloblastoma tumor 
stroma, near the cords/nests of neoplastic odontogenic 
epithelia (arrows head). (C) Illustrates a weak cytoplasmic 
CD90 expression in a unicystic ameloblastoma in the 
capsular connective tissue of the tumor (fibroblasts – asterisk; 
vascular endothelial cells – arrows head). Magnification 



















n % n %
0 1 10 2 28,6 - 
1 - 0 5 71,4 0.003
2 9 90 - 0 - 
Total 10 100 7 100 - 
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in tumor growth, angiogenesis7, progression18, 
infiltration and invasiviness19.
CD90 is an established marker for numerous 
types of human stem cells, especially mesenchymal 
stem cells. It is considered a critical regulator of 
cell-cell and cell-matrix interactions, and plays a 
role in cellular migration and fibrosis, both events 
being considered important for tissue regeneration 
and oncogenesis20. CD90 expression in tumor stroma, 
mainly endothelial and mesenchymal stem cells, 
as well as in tumor-associated fibroblasts, seems 
to play an influential role in disease progression8. 
In the present study, a signif icant CD90 
expression was found in the stroma of all multicystic 
ameloblastoma specimens, whereas most unicystic 
cases showed a weak or nonexistent expression. 
Curiously, in multicystic ameloblastoma, CD90 
staining was detected in the vascular endothelial 
cells and in the stromal fibroblasts near the 
neoplastic odontogenic epithelium. This finding 
highlights the potential of tumor stroma arising 
from an interaction with the neoplastic epithelium 
to mediate the invasive potential of multicystic 
ameloblastomas. This argument is based on the 
premise that when stroma lacks tumor block action, 
it may support tumor progression6. Additionally, 
it is known that tumor growth may be induced 
by the local microenvironment, which is an active 
phenomenon that occurs through the stromal cells 
(fibroblasts and vascular endothelium) and their 
tumor supporting role21. 
The role of stromal cells has been recently 
highlighted in malignant and benign tumors, 
including ameloblastoma22. It has been theorized 
that the fibroblasts close to neoplastic cells can 
secrete inflammatory cytokines, which may induce 
Figure 2. Immunohistochemical expression of P75NTR in multicystic 
and unicystic ameloblastomas. Nuclear P75NTR expression (A) in the 
peripheral ameloblast-like columnar cells and (B) in central areas of 
neoplastic epithelium of a multicystic ameloblastoma. (C) Nuclear 
P75NTR expression in the neoplastic epithelium of a unicystic 














n % n %
1 3 30 7 100 - 
2 1 10 - 0  -
3 3 30  - 0 0.007
4 3 30 - 0  -
Total 10 100 7 100 - 
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osteoclastogenesis through the receptor activator 
of nuclear factor kappa B ligand (RANKL)23. 
Additionally, Sandra et al.24 showed that the 
ameloblastoma cells can secret RANKL and TNFα, 
which may induce osteoclastogenesis through 
stromal osteoclast activation. 
Feng et al.9 suggested that the invasive potential 
of multicystic ameloblastoma could be regulated 
by interactions between the neoplastic and stromal 
cells, by regulating cellular adhesion and migration. 
Their theory was based on the expression of 
Twist, an epithelialmesenchymal transit ion 
(EMT) promoter in multicystic ameloblastomas, 
in stromal regions near the positive neoplastic 
cells. Furthermore, Siar and Ng10 found that 
ameloblastoma stromal fibroblasts and vascular 
endothelium were positive to Twist, proximal 
to posit ive neoplast ic cells. We believe that 
CD90 expression in ameloblastoma, as in other 
tumors25, could play an important role in cellular 
adhesion and migration, serving as an important 
regulator of cell-matrix interactions7. Taking this 
into consideration, the prominent stromal CD90 
expression in the multicystic (versus unicystic) 
ameloblastomas found in the present study could 
be one of the causes of the already known invasive 
behavior of the multicystic type.
In the present study we also analyzed the 
P75NTR expression in ameloblastoma specimens. 
Interestingly, a considerable expression of the 
P75NTR stem cell marker was detected in the 
central areas of the neoplastic epithelium, mostly in 
regions resembling the stellate reticulum or having 
squamous differentiation. P75NTR is a receptor 
for neurotrophins, and is related to pluripotency13. 
P75NTR has been found to be expressed in a 
variety of stem cell types, including embryonic26, 
adult and cancer stem cells15. It is also considered 
a stem cell marker of undifferentiated progenitors 
of the neural crest27.  It is important to emphasize 
that the presence of P75NTR has been linked to 
a high rate of recurrence and aggressiveness of 
some tumors15.  In addition, P75NTR is known as 
a nerve growth factor receptor marker15 and seems 
to participate in the fate of some events of neural 
crest cells, also involving the expression of the 
fibroblast growth factor (FGF)28,29. Recently, Nakao 
et al.30 suggested that FGF subtypes are involved 
in the proliferation of ameloblastomas. This could 
explain the increased P75NTR expression in the 
multicystic ameloblastomas presented here, and 
could also account for its distinct biological behavior 
in multicystic versus unicystic ameloblastomas. 
The study results suggest that the expression 
of P75NTR could be related to ameloblastoma 
pathogenesis, since P75NTR is a marker of 
undifferentiated progenitors of the neural crest, 
which originates the odontoblasts13. Using an 
animal model, Fukumoto et al. (2004)14 showed 
that the expression of Msx2 and P75NTR in mutant 
tooth development is deregulated and increased, 
acquiring the properties of undifferentiated dental 
epithelium and resulting in the development of 
odontogenic tumors. In addition, Juuri et al.12 also 
suggested that stem cell properties are important 
in ameloblastoma formation and invasiveness, thus 
supporting the recurrent nature of some of these 
tumors.  Considering this finding together with our 
results, we can postulate the possible role of P75NTR 
in the neoplastic conversion of the odontogenic 
epithelium present in the ameloblastoma.
Conclusion
To date, there have been no studies addressing 
the expression of CD90 and P75NTR stem cell 
markers in odontogenic tumors, especially in 
ameloblastoma. In this study, an increased expression 
of these two markers was found in multicystic 
ameloblastoma, thereby suggesting behavioral 
biological differences between multicystic and 
unicystic ameloblastomas, as well as a difference 
in ameloblastoma development, probably related 
to altered CD90 and P75NTR expressions.  
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